Efficacy and safety of liposomal doxorubicin in a patient treated for metastatic breast cancer
Journal Title: OncoReview - Year 2015, Vol 5, Issue 2
Abstract
Liposomal doxorubicin is a newer form of chemotherapeutic agents that, due to its own special properties, preferably accumulates in cancer tissue. On the other hand, it shows lower affinity to cardiomyocytes and in this way is less cardiotoxic. As a result of that, there is the possibility to use liposomal form of doxorubicin until disease progression or chemotherapy intolerance in palliative setting, without treatment cessation after reaching the maximum cumulative dose of conventional doxorubicin. In this article we describe the case of a female patient diagnosed with breast cancer who was primary treated with adjuvant treatment, including chemotherapy and in whom a disease recurrence occurred after seven years of observation. As a primary palliative treatment the patient received chemotherapy based on liposomal doxorubicin and cyclofosphamide with a very good tolerance. The initial response was partial remission in lungs and in mediastinal lymph nodes. During the whole course of therapy there were no pathological changes in electrocardiogram, no signs and no symptoms of congestive heart failure, and the left ventricular ejection fraction was within normal limits.
Authors and Affiliations
Joanna Streb, Agnieszka Słowik
Perikardiocenteza i aspekty terapii doosierdziowej u chorych onkologicznych - opis przypadku
Przebieg procesu nowotworowego z towarzyszącym wysiękiem płynu do worka osierdziowego ma zmienną dynamikę, a obraz kliniczny i nasilenie objawów związane są bezpośrednio ze stopniem zaburzeń hemodynamicznych i szybkością...
Long-standing acromegaly in a patient with a pituitary adenoma not visible on MRI
Introduction: Acromegaly in the course of a pituitary microadenoma or neuroendocrine GHRH-secreting tumour (GHRH, growth hormone-releasing hormone) invisible on MRI is very rare. Objective: To present the difficulties in...
Myocardial dysfunction related to trastuzumab therapy – is effective treatment always possible?
Left ventricle systolic dysfunction manifesting during trastuzumab treatment is defined as cardiotoxicity type II. It is characterized by full reversibility after discontinuation of trastuzumab and cardiological pharmaco...
The role of granulocyte colony-stimulating factors in the prevention of neutropenia and febrile neutropenia – the current state of knowledge
Granulocyte colony-stimulating factors, introduced in the 1990s to prevent neutropenic fever, improve patients’ prognosis after myelotoxic chemotherapy. G-CSFs accelerate bone marrow recovery, shortening the duration of...
Advanced pancreatic neuroendocrine tumor patient treated with everolimus – case report
The increasing incidence of gastroenteropancreatic neuroendocrine tumors is caused not exclusively by increasing number of new cases, but also by improved diagnostics. Proper diagnosis and evaluation of tumor differentia...